Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. - Wikidata - awgldk - TriplyDB

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

http://www.wikidata.org/entity/Q34603290

about

Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for hum Current and emerging therapies in unresectable and recurrent gastric cancer Taxanes in the Treatment of Advanced Gastric Cancer Advanced gastric cancer: Current treatment landscape and future perspectives Chemotherapy in Elderly Patients with Gastric Cancer Companion diagnostics for the targeted therapy of gastric cancer Clinical utility of ramucirumab in advanced gastric cancer Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity.A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.A unified model of the hierarchical and stochastic theories of gastric cancer.Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer.Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.

P2860

Q24186222-2C4BF0D8-C586-45EE-99AD-E5B6F5079D54 Q24633301-44BD9A61-3253-45F1-9E94-028F2C281DAB Q26745453-43516207-E25A-4B4B-8567-BC6F7596BFA6 Q26747708-B6F40560-9591-407C-977E-9AA0FF9A3092 Q26764934-35A01D46-E712-4CCE-B37F-67F7A78480A5 Q26771424-FF19AEF0-DA0F-4561-8EDA-60973443BE91 Q26780298-E32BC853-CE4A-40CB-B4EF-49C2BF447271 Q26785665-1A9FBBFF-39B3-473B-974E-0E8F0E397423 Q26798420-3A6B3FCE-7E8A-4326-B402-A17AE70AC43E Q26865057-EF1E14DD-74F9-4307-BFE6-EC576F77FCB7 Q27028095-682C2E28-00F9-4E4E-8A86-EFFB07BF3FAC Q28079750-3886E130-E223-4EE8-98D5-37C31E4141A7 Q28084888-B82490FF-EF06-48D5-9786-6B6688E0D75B Q28544422-D6C09030-3360-4E30-8910-E443DFCC796A Q30837184-DF5977AB-98D2-496E-A537-E0EBCB629EBC Q33386875-DD5D7108-0DAC-41AC-BF33-50F134AA4F33 Q33387432-7B34F153-7CEF-48BE-84BF-392B5C89C6D3 Q33389563-1EEEA83D-4AFC-4832-960E-72EF8E51A794 Q33391384-CAB41B51-52EF-42CB-8D5F-D62CADABC42A Q33396506-B158C021-74A7-4921-9063-89D1027FC7DC Q33397356-165B6D87-08D7-4FB9-B983-94447C61538C Q33399530-49C06D70-9C9B-401B-ADF9-2265542212C6 Q33407676-A1D416C3-BE35-4CB9-8385-BF73A3E50619 Q33408000-254027E7-AB28-428F-85C4-7B7E98AC5F76 Q33413350-AF86F7BA-F2FA-4D57-9662-D94D18BAF4AA Q33413548-D609596D-C950-4C7B-922C-AA7E08919267 Q33416500-78635051-2099-49AF-8C48-6EEA09817E95 Q33420157-CB5755CE-9B92-42FC-9EE3-19993226EE2B Q33421868-D2FBCDD4-10CC-4768-8C59-43E95BDB6815 Q33426501-837A518B-BFA1-41F9-98A0-777EA68D1880 Q33426732-90EC172A-D710-4C3E-ACA4-B25AE40DC12E Q33429869-2D8564FE-82F2-45F2-8325-89EA6BDFDC93 Q33432199-B898D1B6-F888-41A7-87EB-634F943CCC63 Q33442681-A94681D7-AF14-4E87-8487-538206980D98 Q33574315-A9479969-D9AA-4887-9176-E58DEC12BD61 Q33577624-E2F80DE1-05C9-4772-A1A8-85A611C56EFB Q33594906-5BBECC3B-98D1-4AC5-BFF2-52622F2E522C Q33729150-AE4A8616-843E-4C1C-A4BE-5B67B544217A Q33779701-184F5EE5-3C8C-466B-8657-79CA20AAA1B0 Q33849656-B2DF0159-050F-4009-8470-3155AB043CBD

P2860

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

http://www.wikidata.org/entity/Q34603290

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@ast

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@en

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@nl

type

label

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@ast

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@en

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@nl

prefLabel

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@ast

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@en

Capecitabine/cisplatin versus ...... hase III noninferiority trial.

@nl

P1433

Q34603290-0250E4AF-29A6-44FB-BA04-5C8598AEC977

P1476

Q34603290-32531D4A-6679-4801-87B3-32FCEAA1E660

P2093

Q34603290-07E91254-308A-4F9F-B9FF-929E673F4505

Q34603290-14EF0A29-5A59-4A68-809D-B35611217CBC

Q34603290-1C884083-DF43-4C8B-A503-DBF0CA1F8976

Q34603290-21C56748-BC40-4444-B88C-9208C4155FFC

Q34603290-37FB5E46-D937-4B18-A6FD-4A11EFF4EA24

Q34603290-74EFE713-C404-4A03-9AAA-9F2690BF3289

Q34603290-74F4EBE3-CC9B-430E-B4D7-D0EE1C4DDCAF

Q34603290-9359F8CE-6BB8-4A68-8530-1CA8E9C68629

Q34603290-9489553E-2467-4A3E-9ED5-3E52F74727EE

Q34603290-B252A7BA-AF85-48A1-B1A6-70C37B00E8A9

P2860

Q34603290-0F205161-4DCA-4F7C-B899-BAE324A0A06D

Q34603290-143AC3BB-E370-4E9C-933A-C1525E491668

Q34603290-1C43FED9-F0B7-42CC-9A25-41CB5F68F232

Q34603290-4FA27D2A-A9A8-4C71-9B2A-805CC67AC731

Q34603290-79D2337C-2A48-4FB5-B2E6-4A013BF30390

Q34603290-92823899-F075-4F20-A7A4-5378D1943B0D

Q34603290-A19F8422-9C7C-47C0-9C96-40A7411702AC

Q34603290-A1EF702C-3FFB-4B77-9236-8C2B21E4165E

Q34603290-A5410113-106D-4ECC-8F3F-99B9B8AF3801

Q34603290-C979161C-AA4B-4828-A897-05A8A13CD478

P304

Q34603290-2D114C38-4FC1-4F03-8733-48A40ADE8491

P31

Q34603290-3F8B899F-9E38-48C9-B30E-B2F3813AB16A

P356

Q34603290-4249E64B-913B-47AF-8CE4-149910E33B22

P433

Q34603290-2495873A-98EF-40B7-B9B2-AD04A01CBE1F

P478

Q34603290-D5459148-1B57-4DF9-B27A-3D3D36337B1A

P50

Q34603290-356B3ABC-0118-49CC-BE7D-B105A34F5DC8

P577

Q34603290-CFF37A6F-D760-439B-8662-26B68D54E811

P5875

Q34603290-8AB2BDBF-ACF7-4173-83A8-9CEB7B03604E

P698

Q34603290-B1A5A84D-D6FC-4BBB-933E-0083428FEAED

P921

Q34603290-058B3FA7-2B2A-4F6E-AD16-2EC95B531450

P356

P1433

Annals of Oncology

P1476

Capecitabine/cisplatin versus ...... phase III noninferiority trial

@en

P2093

D-B Shin

http://www.w3.org/2001/XMLSchema#string

G Forster

http://www.w3.org/2001/XMLSchema#string

J Chen

http://www.w3.org/2001/XMLSchema#string

J Santamaria

http://www.w3.org/2001/XMLSchema#string

J Wang

http://www.w3.org/2001/XMLSchema#string

J Xiong

http://www.w3.org/2001/XMLSchema#string

L Zheng

http://www.w3.org/2001/XMLSchema#string

M Lichinitser

http://www.w3.org/2001/XMLSchema#string

M Philco-Salas

http://www.w3.org/2001/XMLSchema#string

P I McCloud

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.

Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Capecitabine in the treatment of advanced gastric cancer.

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Design and analysis of non-inferiority mortality trials in oncology.

A pilot phase II study of capecitabine in advanced or recurrent gastric cancer.

P304

666-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDN717

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23800837

http://www.w3.org/2001/XMLSchema#string

P698

19153121

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial